Axon Enterprise (NASDAQ:AXON) Stock Gets Price Target Trim from Barclays

Axon Enterprise (NASDAQ:AXON) had its target price lowered by Barclays from $688.00 to $507.00 in a report released on Monday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other analysts have also recently weighed in on the company. Northcoast Research boosted their price target on Axon Enterprise from $650.00 to $680.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Argus increased their price objective on Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday, November 3rd. Morgan Stanley raised their price objective on Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, TD Cowen reduced their target price on Axon Enterprise from $825.00 to $800.00 and set a “buy” rating for the company in a report on Monday, October 26th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $612.18.

Axon Enterprise Stock Up 4.3%

AXON stock opened at $315.42 on Monday. The firm has a market cap of $25.68 billion, a PE ratio of 101.10, a PEG ratio of 5.75 and a beta of 1.48. Axon Enterprise has a 1 year low of $291.45 and a 1 year high of $665.07. The company has a fifty day simple moving average of $426.24 and a 200 day simple moving average of $470.65. The company has a current ratio of 3.00, a quick ratio of 2.60 and a debt-to-equity ratio of 0.76.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.89 by ($0.17). Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. The business had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. During the same period in the previous year, the company earned $1.17 earnings per share. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. Sell-side analysts anticipate that Axon Enterprise will post 2.10 EPS for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the completion of the transaction, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at approximately $1,587,036,927.88. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 1,017 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $480.45, for a total transaction of $488,617.65. Following the completion of the sale, the insider owned 56,264 shares in the company, valued at $27,032,038.80. This represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 37,397 shares of company stock valued at $21,234,034. 4.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in Axon Enterprise during the 3rd quarter worth approximately $10,043,000. GW&K Investment Management LLC increased its holdings in Axon Enterprise by 79.3% during the 3rd quarter. GW&K Investment Management LLC now owns 434 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 192 shares in the last quarter. USS Investment Management Ltd raised its position in Axon Enterprise by 10.4% in the 3rd quarter. USS Investment Management Ltd now owns 84,022 shares of the biotechnology company’s stock valued at $35,507,000 after purchasing an additional 7,900 shares during the last quarter. Private Advisor Group LLC raised its position in Axon Enterprise by 71.8% in the 3rd quarter. Private Advisor Group LLC now owns 15,382 shares of the biotechnology company’s stock valued at $6,499,000 after purchasing an additional 6,426 shares during the last quarter. Finally, Ieq Capital LLC raised its position in Axon Enterprise by 37.4% in the 3rd quarter. Ieq Capital LLC now owns 903 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 246 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axon Enterprise

Here are a few of the latest headlines about AXON:

• Positive Sentiment: Axon’s integrated public-safety hardware and software ecosystem, along with continued revenue growth, are cited as reasons it could remain a long-term growth company despite its 2026 share-price decline. 3 Superior Growth Stocks That Can Outperform for the Next 10 Years
• Negative Sentiment: Axon’s third-quarter adjusted EPS missed Wall Street expectations, and cautious guidance contributed to a sharp share decline. The company also said federal contract delays shifted $130 million of revenue out of 2026, weighing on near-term expectations. Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
• Negative Sentiment: Several law firms have announced investigations into potential securities-law claims related to Axon’s earnings report. These are allegations under investigation, not findings of wrongdoing, but add a source of uncertainty for investors. Levi & Korsinsky investor investigation notice

About Axon Enterprise

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.